Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

For patients with stage IA non-small cell lung cancer (NSCLC), lung resections, including lobectomy and segmentectomy, are ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

This guide will help you understand how NSCLC is treated, potential side effects, and how to navigate life beyond cancer.

Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...

While surgery has been a primary treatment option for some early-stage NSCLC patients, recurrence rates of 30% to 55% highlight the need for additional perioperative interventions. “Given the ...

The CONVERGE study evaluates NBTXR3's efficacy in stage III unresectable NSCLC with standard chemoradiation and durvalumab. NBTXR3, a hafnium oxide nanoparticle, is activated by radiotherapy to induce ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...